Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
NCT ID: NCT04346862
Last Updated: 2020-04-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
636 participants
INTERVENTIONAL
2016-01-26
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease
NCT02955706
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients
NCT05050604
Metformin in Alzheimer's Dementia Prevention
NCT04098666
A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients
NCT02648906
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
NCT00013923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acetyl-L-carnitine hydrochloride
Acetyl-L-carnitine hydrochloride 500mg
The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
Placebo
Placebo
The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acetyl-L-carnitine hydrochloride 500mg
The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
Placebo
The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with chronic cerebrovascular disease, who have modified Fazekas scale grade 2 \~ 3
* Patients wtih a diagnosis of MCI
* MOCA-K of 23 or less
* Patients who provided a signed written informed consent form
Exclusion Criteria
* Patiens previously treated with dementia
* Patients who received a nootropic agent or thyroid hormone within 4 weeks of visit 1
* Patients with cognitive impairment due to diseases other than cerebrovascular disease
* Patients with severe depression, schizophrenia, alcoholism, and drug dependence
55 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanmi Pharmaceutical Company Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catholic Kwandong University International St. Mary'S Hospital
Incheon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Young-in Kim, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HM-VASCA-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.